ArticleEuropean journal of radiology2021
Altered in vivo brain GABA and glutamate levels are associated with multiple sclerosis central fatigue.
Article in European journal of radiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 34 citations in OpenAlex.
- 1,3,4 oxadiazole derivative attenuates neurotransmitter-mediated inflammatory response in EAE model of multiple sclerosis.Scientific reports · 2026Article
- Network Localization of Fatigue in Multiple Sclerosis.Annals of clinical and translational neurology · 2026Article
- Gray matter sodium accumulation and atrophy in relapsing-remitting multiple sclerosis correspond to neurotransmitter maps.European radiology · 2026Article
- Impact of a GABA-ProducingFASEB bioAdvances · 2026Article
- Neurophysiological, imaging and neurobiological markers of central fatigue in multiple sclerosis.Brain communications · 2026Article
- A neuropsychological perspective on sensory hypersensitivity after acquired brain injury.Brain communications · 2026Review
- Neurotransmitters as regulators of autoimmunity: mechanisms and translational targeting.NPJ autoimmunity · 2026Review
- Enhanced therapeutic potential of paeoniflorin and vitamin B12 in intracerebropeduncle ethidium bromide-induced multiple sclerosis-like pathology.Frontiers in pharmacology · 2026Article
- Impaired myelination in multiple sclerosis organoids: p21 links oligodendrocyte dysfunction to disease subtype.Frontiers in cellular neuroscience · 2026Article
- Mapping the neural and molecular basis underlying fatigue in Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Microbiota-Derived SCFAs in Multiple Sclerosis: From Immune Priming to Neurodegeneration.Molecular neurobiology · 2025Review
- Association of decreased thalamic neurotransmitter level with sensorimotor tract damage in patients with relapsing-remitting multiple sclerosis.Quantitative imaging in medicine and surgery · 2025Article
- Effects of Dietary and Probiotic Interventions in Patients with Metabolic Syndrome and Obstructive Sleep Apnea.Clinics and practice · 2025Article
- Decoding tinnitus progression: neurochemical shifts in the anterior cingulate cortex revealed by magnetic resonance spectroscopy.Frontiers in neuroscience · 2025Article
- Resting state functional connectivity modifications in monoaminergic circuits underpin fatigue development in patients with multiple sclerosis.Molecular psychiatry · 2024Article
- Association of Cortical Lesions With Regional Glutamate, GABA,Neurology · 2024Article
- Exercise-Induced Central Fatigue: Biomarkers and Non-Medicinal Interventions.Aging and disease · 2024Review
- Farnesol brain transcriptomics in CNS inflammatory demyelination.Clinical immunology (Orlando, Fla.) · 2023Article
- Fatigue in fluctuating Parkinson's disease patients: possible impact of safinamide.Journal of neural transmission (Vienna, Austria : 1996) · 2023Article
- Ongoing oxidative stress in individuals with post-acute sequelae of COVID-19.NeuroImmune pharmacology and therapeutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
purposeFatigue is a common symptom in patients with multiple sclerosis (MS) with unknown pathophysiology. Dysfunction of the GABAergic/glutamatergic pathways involving inhibitory and excitatory neurotransmitters such as γ-aminobutyric acid (GABA) and glutamine + glutamate pool (Glx) have been implicated in several neurological disorders. This study is aimed to evaluate the potential role of GABA and Glx in the origin of central fatigue in relapse remitting MS (RRMS) patients.
methods24 RRMS patients and 16 age- and sex-matched healthy controls (HC) were scanned using Mescher-Garwood point resolved spectroscopy (MEGA-PRESS) with a 3 T system to quantify GABA+ and Glx from prefrontal (PFC) and sensorimotor (SMC) cortices. Self-reported fatigue status was measured on all participants using the Modified Fatigue Impact Scale (MFIS).
resultsRRMS patients had higher fatigue scores relative to HC (p ≤ 0.05). Compared to HC, Glx levels in RRMS patients were significantly decreased in SMC (p = 0.04). Significant correlations were found between fatigue scores and GABA+ (r = -0.531, p = 0.008) and Glx (r = 0.511, p = 0.018) in PFC. Physical fatigue was negatively correlated with GABA+ in SMC and PFC (r = -0.428 and -0.472 respectively, p ≤ 0.04) and positively with PFC Glx (r = 0.480, p = 0.028).
conclusionThe associations between fatigue and GABA + and Glx suggest that there might be dysregulation of GABAergic/glutamatergic neurotransmission in the pathophysiological mechanism of central fatigue in MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.